Endo Pharmaceuticals Holdings Inc. (ENDP) said the U.S. FDA has informed that there is no need to convene a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review Endo's New Drug Application for the new oral formulation of long-acting oxymorphone.
FDA has also informed that it has gleaned sufficient information from previous advisory committee meetings to enable the division to reach a decision on the company's application without additional external expert input.
The new formulation of long-acting Oxymorphone designed to be crush-resistant, is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.
The action date set by FDA under the Prescription Drug User Fee Act is Jan. 7, 2011.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.